Drug Profile
Zalifrelimab - Agenus
Alternative Names: AGEN-1884; RebmAb-600; UGN-301Latest Information Update: 07 Jul 2023
Price :
$50
*
At a glance
- Originator 4-Antibody; Ludwig Institute for Cancer Research
- Developer Agenus; Betta Pharmaceuticals Co Ltd; Nelum; Recepta biopharma; UroGen Pharma
- Class Antineoplastics; Immunoglobulins; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cervical cancer; Haemangiosarcoma; Non-small cell lung cancer; Soft tissue sarcoma
- Phase I/II Pancreatic cancer; Solid tumours
- Phase I Bladder cancer
- No development reported Cancer
Most Recent Events
- 02 Jun 2023 Efficacy and adverse events data from a phase II trial in soft tissue sarcoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 31 Dec 2022 Agenus terminates its license to Recepta Biopharma for Zalifrelimab in South America